| 15.67 -3.06 (-16.34%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.79 |
1-year : | 22.93 |
| Resists | First : | 16.94 |
Second : | 19.63 |
| Pivot price | 16.92  |
|||
| Supports | First : | 12.59 |
Second : | 10.47 |
| MAs | MA(5) : | 17.76 |
MA(20) : | 16.23 |
| MA(100) : | 21.13 |
MA(250) : | 18.8 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.2 |
D(3) : | 73.8 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 34.09 | Low : | 7.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GLSI ] has closed above bottom band by 20.6%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.97 - 19.06 | 19.06 - 19.14 |
| Low: | 14.08 - 14.16 | 14.16 - 14.22 |
| Close: | 15.55 - 15.68 | 15.68 - 15.79 |
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Tue, 11 Aug 2026
Greenwich LifeSciences (GLSI) posts higher H1 2026 loss and flags going concern risk - Stock Titan
Mon, 10 Aug 2026
Greenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027 - Quiver Quantitative
Mon, 10 Aug 2026
Greenwich LifeSciences Directors, Officers Face 100% Lock-Up to 2027 - Stock Titan
Wed, 22 Jul 2026
UK approval could add 5-10 sites to Greenwich LifeSciences trial - Stock Titan
Tue, 21 Jul 2026
Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me - Seeking Alpha
Mon, 20 Jul 2026
Greenwich trial opens enrollment to patients representing about 55% of population - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 47.9 (%) |
| Held by Institutions | 12.2 (%) |
| Shares Short | 1,540 (K) |
| Shares Short P.Month | 1,460 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -236 % |
| Return on Equity (ttm) | -986.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -9.86 |
| PEG Ratio | 0 |
| Price to Book value | 43.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|